Healthcare

• This is the second FDA Orphan Drug Designation for sovleplenib, following its October 2026 designation for primary immune thrombocytopenia (ITP).

• Lacutamab Phase 3 TELLOMAK-3 trial is on track for first patient dosing in Q1 2027, with an FDAAccelerated Approvalfiling planned for H2 2027.

• The ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program are fully enrolled, with data expected mid-2027 and mid-2028, respectively.

• Ryoncil (remestemcel-L-rknd) was highlighted as a first-line treatment option after steroids for pediatric acute graft-versus-host disease

• 46% of participants on lorundrostat 50 mg achieved the AHA/ACC systolic BP target of less than 130 mmHg at Week 12

• The company expanded its relationship with HealthCareRoyaltythrough a $125 million financing linked to mazdutide royalty payments from Eli Lilly.

•Net Incomerose 11% to $29.5 million, or $0.72 per diluted share, while adjusted EBITDA increased 4% to $64.3 million.